The FDA authorized marketing of on! PLUS nicotine pouches, a positive catalyst for Altria Group (MO) that supports its transition to smoke-free products and signals a potentially more favorable regulatory backdrop for nicotine pouches following the FDA’s new streamlined review program, Goldman Sachs analyst Bonnie Herzog tells investors in a research note. The approval enables an immediate test-market relaunch with a path to national rollout by 2H26, reinforcing the firm’s confidence in Altria’s’s ability to deliver mid-single-digit adjusted EPS growth through 2028 and beyond and supporting a positive stock reaction. Goldman Sachs has a Buy rating and $72 price target on Altria shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MO:
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 20
- FDA authorizes marketing of 6 nicotine pouch products made by Helix Innovations
- Altria (MO) Wins FDA Approval for on! PLUS, Expands in Oral Nicotine Market
- Altria Group price target lowered to $64 from $66 at BofA
- Altria Group call volume above normal and directionally bullish